Clinical trials:

  • NOR-MS: Comparing treatment with cladribine and rituximab
  • NEVROVAX: Study of responses to vaccination against influenza and COVID-19
  • LEM-PASS: Safety follow-up after treatment with alemtuzumab (Sponsor Sanofi)
  • CLAD-CROSS: A prospective study of safety and efficacy when switching to cladribine (Sponsor Merck)
  • COMB157G23101: A prospective study of efficacy and safety when switching from dimethylfumarate or fingolimod to ofatumumab (Sponsor Novartis)
  • GEMINI: Double blind, randomized study comparing BTKi-inhibitor with teriflunomide in RRMS (Sponsor Sanofi)
  • HERCULES: Double blind, randomized study comparing BTKi-inhibitor with placebo in SPMS (Sponsor Sanofi)
 
Page visits: 598